(Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (FY)Dec 31, 2019 | |
---|---|---|---|---|---|---|---|---|
Turnover | --2.53B | 6.27%5.08B | 39.95%4.78B | 23.90%2B | 43.70%3.42B | --1.61B | -4.66%2.38B | --2.49B |
Operating income | 2.53B | 6.27%5.08B | 39.95%4.78B | 23.90%2B | 43.70%3.42B | 1.61B | -4.66%2.38B | 2.49B |
Cost of sales | ---2.23B | -4.26%-4.4B | -39.30%-4.22B | -25.33%-1.8B | -44.86%-3.03B | ---1.44B | 2.83%-2.09B | ---2.15B |
Operating expenses | -2.23B | -4.26%-4.4B | -39.30%-4.22B | -25.33%-1.8B | -44.86%-3.03B | -1.44B | 2.83%-2.09B | -2.15B |
Gross profit | 302.94M | 21.36%681.24M | 45.00%561.33M | 12.23%198.35M | 35.25%387.11M | 176.73M | -16.15%286.22M | 341.36M |
Selling expenses | ---150.81M | -21.83%-316.23M | -34.92%-259.57M | -32.90%-95.03M | -58.44%-192.39M | ---71.51M | 6.56%-121.42M | ---129.95M |
Administrative expenses | ---52.34M | -11.43%-99.24M | -38.20%-89.06M | -34.80%-40.43M | -4.92%-64.44M | ---29.99M | 15.98%-61.42M | ---73.1M |
Research and development expenses | ---91.97M | -25.85%-189.4M | -57.05%-150.5M | 1.41%-44.84M | -14.73%-95.83M | ---45.48M | -20.35%-83.52M | ---69.4M |
Impairment and provision | ---474K | 44.97%-908K | -281.72%-1.65M | 102.38%316K | 114.71%908K | ---13.29M | 20.58%-6.17M | ---7.77M |
-Other impairment is provision | ---474K | 44.97%-908K | -281.72%-1.65M | 102.38%316K | 114.71%908K | ---13.29M | 20.58%-6.17M | ---7.77M |
Special items of operating profit | --47.02M | -0.46%64.93M | 96.72%65.22M | 197.92%43.46M | 11.16%33.16M | --14.59M | 17.44%29.83M | --25.4M |
Operating profit | 54.36M | 11.61%140.39M | 83.58%125.78M | 99.09%61.83M | 57.47%68.52M | 31.06M | -49.71%43.51M | 86.53M |
Financing income | --23.93M | 55.25%32.66M | 158.39%21.04M | 53.42%6.21M | 20.82%8.14M | --4.05M | -26.92%6.74M | --9.22M |
Financing cost | ---11.41M | 11.26%-21.98M | -61.04%-24.77M | -85.42%-13.99M | -122.59%-15.38M | ---7.54M | -2.17%-6.91M | ---6.76M |
Share of profits of associates | ---178K | -63.68%73K | -35.99%201K | 195.71%207K | 1,465.22%314K | --70K | 52.08%-23K | ---48K |
Special items of earning before tax | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---4.31M |
Earning before tax | 66.7M | 23.63%151.14M | 98.48%122.25M | 96.37%54.26M | 42.19%61.59M | 27.63M | -48.82%43.32M | 84.63M |
Tax | ---716K | -31.18%-5.53M | -80.95%-4.22M | -348.63%-2.45M | 23.22%-2.33M | --987K | 79.61%-3.04M | ---14.89M |
After-tax profit from continuing operations | 65.99M | 23.36%145.61M | 99.17%118.03M | 81.03%51.8M | 47.12%59.26M | 28.62M | -42.24%40.28M | 69.74M |
Earning after tax | 65.99M | 23.36%145.61M | 99.17%118.03M | 81.03%51.8M | 47.12%59.26M | 28.62M | -42.24%40.28M | 69.74M |
Minority profit | ---- | ---- | ---- | ---- | ---- | ---- | -111.43%-12K | --105K |
Profit attributable to shareholders | 65.99M | 23.36%145.61M | 99.17%118.03M | 81.03%51.8M | 47.07%59.26M | 28.62M | -42.14%40.29M | 69.63M |
Basic earnings per share | 0.162 | 16.22%0.43 | -80.00%0.37 | 82.02%1.62 | 46.83%1.85 | 0.89 | -42.20%1.26 | 2.18 |
Diluted earnings per share | 0.159 | 16.22%0.43 | -80.00%0.37 | 82.02%1.62 | 46.83%1.85 | 0.89 | -42.20%1.26 | 2.18 |
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
Audit Opinions | -- | Unqualified Opinion | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
Auditor | -- | PricewaterhouseCoopers | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | -- | PricewaterhouseCoopers | PricewaterhouseCoopers |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data
No Data